Q-Line Biotech IPO Review: India’s IVD Diagnostics Manufacturer Opens 21 May 2026 at Rs 326-343 With GMP Signalling 12-19% Premium

The Q-Line Biotech IPO opens for subscription on 21 May 2026 on the NSE SME platform with a price band of Rs 326 to Rs 343 per share. The Rs 214 crore issue is a 100 percent fresh issue with all proceeds going directly to the company. Q-Line Biotech Limited is a Surat-based In-Vitro Diagnostic (IVD) products manufacturer with over 15 years of industry experience, serving 150-plus national and international clients across pathology, clinical diagnostics and medical equipment segments.

The Q-Line Biotech IPO GMP stands at Rs 42 to Rs 65 per share as of 18 to 19 May 2026, implying an expected listing price of Rs 385 to Rs 408, representing a potential listing premium of approximately 12.2 to 18.95 percent over the upper band of Rs 343. The grey market consensus of Rs 42 (steady GMP per IPOGuru) versus a high of Rs 65 (IPOWatch) reflects some divergence in grey market sources. Investors should take the lower Rs 42 as the more conservative grey market signal.

Q-Line Biotech IPO Key Details

• IPO Open Date: 21 May 2026 (Wednesday)
• IPO Close Date: 25 May 2026 (Sunday — last day to apply)
• Allotment Date: 26 May 2026
• Credit of Shares: 27 May 2026
• Listing Date: 29 May 2026 (NSE SME)
• Price Band: Rs 326 to Rs 343 per share
• Face Value: Rs 10 per share
• Issue Size: Rs 214 crore (62.53 lakh shares, 100% fresh issue)
• Lot Size: 400 shares per lot
• Minimum Retail Application: 2 lots (800 shares) at Rs 2,74,400 at upper band
• Minimum HNI Application: 3 lots (1,200 shares) at Rs 4,11,600
• Category Split: QIB 50%, Retail 35%, NII 15%
• GMP (18-19 May 2026): Rs 42 to Rs 65 (12.2 to 18.95% implied premium)
• Implied Listing Price (conservative GMP Rs 42): Rs 385 per share
• Implied Listing Price (high GMP Rs 65): Rs 408 per share
• Lead Managers: Hem Securities Ltd and Share India Capital Services Pvt Ltd
• Registrar: Purva Sharegistry (India) Pvt Ltd
• Market Maker: Hem Finlease Pvt Ltd
• Promoters: Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal
• DRHP Filing Date: 30 September 2025

Track Q-Line Biotech IPO subscription and GMP live on the Check the Univest Screener for live data.

About Q-Line Biotech: Business and Products

Q-Line Biotech Limited has been active in the diagnostic industry for over 15 years, incorporated in 2010 (with the company’s effective operational history from 2013 as referenced in one source) in Surat, Gujarat. The company manufactures and supplies In-Vitro Diagnostic (IVD) products, medical diagnostic equipment, reagents, rapid test kits, and pathology instruments. IVD products are used to perform tests on samples such as blood, urine and tissue that have been taken from the human body, to detect diseases, conditions and infections.

The company has a presence across all four regions of India through its distribution network and serves 150-plus national and international clients. As of March 31, 2026, the manufacturing team includes 126 permanent employees and 223 third-party contract workers collaborating on R&D, supply chain and quality control. The R&D team of 23 professionals (7.35 percent of the permanent workforce as of March 2025) focuses on reverse engineering, quality control and new product development including indigenous diagnostic analysers.

• Key IVD Products: Diagnostic reagents, rapid test kits, pathology instruments, medical diagnostic equipment, biochemistry analysers
• Indigenous Analysers: Selectra Pro M, Medonic M20, Q-Count 5 (Make in India diagnostic instruments)
• Clients: 150+ national and international clients across all four Indian regions
• R&D Focus: Reverse engineering, IVD product innovation, import substitution in diagnostics

Q-Line Biotech IPO Financials

• FY25 Revenue from Operations: Rs 322.58 crore (up 56.3% from Rs 206.45 crore in FY24)
• FY25 Net Profit (PAT): Rs 28.13 crore (DOWN from Rs 34.44 crore in FY24 — a 18.3% decline)
• FY25 PAT Margin: Approximately 8.7% (down from 16.7% in FY24 as revenue grew faster than profit)
• Revenue Growth: Exceptional 56.3% year-on-year revenue growth in FY25
• Profit Direction: Declining despite revenue growth — a key risk flag requiring RHP review

Q-Line Biotech IPO Use of Proceeds

• Working Capital Requirements: Rs 110 crore — the largest allocation, to fund raw material procurement, debtor cycles and expanded operations
• Debt Repayment: Rs 90 crore — to prepay or repay outstanding borrowings, reducing interest burden
• General Corporate Purposes: Remaining proceeds for operational and administrative requirements

Tap to Access Best Research Pieces on Univest

Key Strengths of Q-Line Biotech IPO

• India’s IVD Market Growth: India’s diagnostic industry is growing rapidly driven by rising healthcare awareness, government health insurance coverage under Ayushman Bharat and expansion of diagnostic labs in tier 2 and tier 3 cities. Q-Line is well-positioned in this structural growth market.
• Make in India Diagnostics: The development of indigenous diagnostic analysers (Selectra Pro M, Q-Count 5) aligns with the government’s Atmanirbhar Bharat push for domestic medical devices, potentially making Q-Line eligible for production-linked incentive benefits.
• 56% Revenue Growth: FY25 revenue growth of 56.3 percent is exceptional for a manufacturing business and demonstrates strong demand for Q-Line’s IVD product range.
• Diversified Product Range: Reagents, rapid test kits, pathology instruments and diagnostic analysers across multiple disease diagnostic areas provide revenue diversification.
• 15-Plus Years of Industry Experience: A long operational track record in the diagnostic industry is a credibility signal for institutional buyers and hospital procurement decision-makers.

Key Risks and Concerns in the Q-Line Biotech IPO

• PAT Decline Despite Revenue Growth: FY25 PAT fell to Rs 28.13 crore from Rs 34.44 crore even as revenue grew 56 percent. This means the incremental revenue growth delivered diminishing profit returns — a margin compression story that warrants detailed investigation in the RHP. Input cost inflation, higher employee costs or regulatory compliance expenses may be driving this.
• Working Capital Heavy Balance Sheet: Rs 110 crore (51.4% of total IPO proceeds) going to working capital indicates significant cash flow strain in the business. A working-capital-heavy diagnostic manufacturer needs careful scrutiny of debtor and inventory cycles.
• Rs 90 Crore Debt Repayment From Proceeds: The fact that Rs 90 crore of the Rs 214 crore fresh issue (42% of proceeds) goes to debt repayment suggests Q-Line has accumulated significant borrowings that were not being effectively serviced from operations.
• High Minimum Investment: The minimum retail application of Rs 2,74,400 (800 shares at Rs 343) is among the highest minimum lot investments in current NSE SME IPOs, limiting participation to investors with higher capital availability.
• Large Issue for NSE SME: At Rs 214 crore, this is a relatively large NSE SME issue. Larger SME issues tend to have lower Grey Market Premiums because the limited oversubscription structure makes it harder for the grey market to build high-conviction premium forecasts. The Rs 42 conservative GMP is consistent with this dynamic.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces on Q-Line Biotech IPO subscription tracker and NSE SME IPO calendar!

GMP Analysis: What Rs 42-65 Tells Us

The Q-Line Biotech IPO has a divergent GMP picture across grey market sources as of 19 May 2026: IPOWatch shows Rs 65 (18.95% premium, implied listing Rs 408) while IPOGuru shows a steadier Rs 42 (12.2% premium, implied listing Rs 385). This divergence is unusual and may reflect different grey market participant groups, with the Rs 42 level being the more consistent and conservative read. IPOWatch’s Rs 65 may be based on a smaller number of transactions.

For application decision purposes, the conservative Rs 42 GMP should be used: an expected listing gain of approximately Rs 33,600 on the minimum retail lot (800 shares × Rs 42) on a capital outlay of Rs 2,74,400, representing a 12.2 percent return on capital blocked. GMP can change materially before the 29 May listing and is unofficial.

Q-Line Biotech IPO: Should You Apply?

IPOWatch recommends applying for the Q-Line Biotech IPO for the long term, noting the GMP and the structural growth of India’s diagnostic market. However, the PAT decline from Rs 34.44 crore to Rs 28.13 crore despite 56 percent revenue growth is a major red flag that demands careful reading of the RHP before applying. If PAT margins are compressing structurally due to pricing pressure in the IVD market or input cost inflation, the long-term investment case weakens significantly.

For listing gain investors at the Rs 42 GMP, the 12.2 percent expected return on the Rs 2,74,400 minimum investment is reasonable. For long-term investors, the margin compression trend makes this a cautious apply rather than a strong conviction buy. Consult a SEBI-registered advisor and read the RHP before investing in the Q-Line Biotech IPO.

Conclusion

The Q-Line Biotech IPO opens 21 May 2026 on NSE SME at Rs 326 to Rs 343 for a Rs 214 crore fresh issue. The Surat IVD diagnostics manufacturer’s 56 percent revenue growth and India diagnostic market tailwind are genuine positives. GMP of Rs 42 (conservative) to Rs 65 (high) signals a 12 to 19 percent listing premium expectation. However, PAT declining from Rs 34.44 crore to Rs 28.13 crore despite revenue growth, Rs 90 crore of proceeds going to debt repayment and the high minimum investment of Rs 2,74,400 are key risk flags. Apply based on fundamental conviction after reading the RHP. Track live subscription and GMP on Univest from 21 May.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

FAQs on Q-Line Biotech IPO

When does the Q-Line Biotech IPO open and close?

Ans. The Q-Line Biotech IPO opens on 21 May 2026 and closes on 25 May 2026. Allotment is on 26 May, share credit on 27 May and listing on NSE SME is on 29 May 2026.

What is the Q-Line Biotech IPO GMP today?

Ans. The Q-Line Biotech IPO GMP stands at Rs 42 (IPOGuru, steady on 18 May) to Rs 65 (IPOWatch). The conservative Rs 42 GMP implies a listing price of approximately Rs 385 (12.2% premium). The Rs 65 GMP implies Rs 408 (18.95% premium). GMP is unofficial and volatile. Apply based on fundamentals, not GMP alone.

What does Q-Line Biotech do?

Ans. Q-Line Biotech Limited manufactures and supplies In-Vitro Diagnostic (IVD) products including diagnostic reagents, rapid test kits, pathology instruments, medical diagnostic equipment and indigenous analysers (Selectra Pro M, Q-Count 5). The company has 15-plus years in the diagnostic industry and serves 150-plus national and international clients from its Surat, Gujarat operations.

What is the minimum investment for Q-Line Biotech IPO?

Ans. The minimum retail application for the Q-Line Biotech IPO is 2 lots of 400 shares each (800 shares total) at the upper band of Rs 343, requiring Rs 2,74,400. HNI investors must apply for a minimum of 3 lots (1,200 shares) at Rs 4,11,600.

Should I apply for the Q-Line Biotech IPO?

Ans. The Q-Line Biotech IPO has a supportive GMP and strong revenue growth story in IVD diagnostics. However, the PAT decline from Rs 34.44 crore to Rs 28.13 crore, Rs 90 crore of debt repayment from proceeds and a high minimum investment of Rs 2,74,400 are concerns. IPOWatch recommends applying for the long term. Consult a SEBI-registered advisor before making any investment decision.